WO2003103685A1 - A method of treating human skin and a skin care composition for use in such a method - Google Patents
A method of treating human skin and a skin care composition for use in such a method Download PDFInfo
- Publication number
- WO2003103685A1 WO2003103685A1 PCT/NL2003/000420 NL0300420W WO03103685A1 WO 2003103685 A1 WO2003103685 A1 WO 2003103685A1 NL 0300420 W NL0300420 W NL 0300420W WO 03103685 A1 WO03103685 A1 WO 03103685A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- skin
- composition
- estrogenic component
- estrogenic
- cosmetically acceptable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/004—Aftersun preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
Definitions
- the present invention relates to a cosmetic method of treating human skin by delivering an estrogenic component to said skin. More particularly, the invention is concerned with such a method that comprises applying to the skin a composition containing an estrogenic component and a cosmetically acceptable vehicle.
- Another aspect of the invention concerns a method of therapeutic method of treating or preventing vaginal dryness or acne and a therapeutic method of promoting wound healing, which methods comprise the delivery of an estrogenic component to vaginal or skin epithelium
- a skin care composition comprising an estrogenic component and a cosmetically acceptable vehicle.
- the human skin consists of two major layers, the bottom thicker layer (dermis) and the top thinner layer (epidermis). Dermis is the layer which provides the strength, elasticity and the thickness to the skin.
- the main cell type of the dermis is the f ⁇ broblast, which is responsible for synthesis and secretion of all the dermal matrix components such as collagen, elastin and glycosaminoglycans.
- Collagen provides the strength, elastin the elasticity and glycosaminoglycans the moistness and plumpness of the skin. With ageing, the thickness of the dermal layer is reduced and this is believed to be partially responsible for the formation of wrinkles in ageing skin.
- the top layer of human skin or the epidermis which provides the resilience and the barrier properties of the skin, is composed of many different cell types including keratinocytes, melanocytes and langerhans cells.
- Keratinocyte is the major cell type of the epidermis (75-80% of the total number of cells in the human epidermis).
- Richards et al. reported that estrogen stimulates secretion of a protein, prolactin, by human dermal f ⁇ broblast cells and that prolactin then stimulates proliferation of keratinocytes (Richards et al., Human Dermal Fibroblasts Express Prolactin In Vitro., J. Invest. Dermatol. (1996), 106: 1250).
- Estrogens and synthetic compounds which act like estrogens are known to increase the thickness of the dermal layer and to reduce wrinkle formation in the ageing skin.
- the changes in the skin such as skin dryness, loss of skin elasticity and plumpness occurring after menopause is attributed to the lack of estrogen production.
- Estrogen therapy prevents or slows down many of these changes associated with ageing skin (Creidi et al., "Effect of a conjugated estrogen cream on ageing facial skin", Maturitas, (1994) 19, p. 211).
- Some of the effects of estrogen on skin include: increase in skin thickness and disappearance of fine wrinkles, increase of the mitotic rate of the epidermis, reduction in the size and activity of the sebaceous gland , slow down of the rate of hair growth, stimulation of collagen turnover and increase in the production of hyaluronic acid and glycosaminoglycan synthesis of the fibroblasts (Pugliese, Menopausal skin, Skin Inc., March/April 1994: p 69-77).
- the present invention provides a particularly effective method of improving or preventing the condition of wrinkled, lined, dry, flaky, aged or photodamaged skin and of improving skin thickness, elasticity, flexibility and plumpness, which method includes applying to the skin a composition that contains an estrogenic component and a cosmetically acceptable carrier.
- the present invention encompasses a cosmetic method of increasing fibroblast and epidermal skin cell proliferation in human skin by applying to the skin the inventive composition.
- the present method may be applied to human skin which is already dry, flaky, lined, wrinkled, aged, photodamaged, or to healthy skin to prevent or reduce such deteriorative changes.
- the invention also concerns a therapeutic method of treating or preventing vaginal dryness as well as a method of promoting wound healing, which methods comprise the delivery of the composition as described herein before to the vaginal or skin epithelium.
- Ri, R 2 , R 3 , R_ independently are a hydrogen atom, a hydroxyl group or an alkoxy group with 1-5 carbon atoms; each of R 5 , Re. z is a hydroxyl group; no more than 3 of Ri, R 2 , R 3 , R 4 are hydrogen atoms.
- a known representative of this group of estrogenic substances is 1,3,5 (10)-estratrien-3, 15 ,16 ⁇ ,17 ⁇ -tetrol, also known by the names of estetrol, oestetrol and 15o_-hydroxyestriol. Estetrol is an estrogen that is produced by the fetal liver during human pregnancy.
- estradiol metabolism as a control of its hormonal action-uterotrophic activity of estradiol metabolites.
- Endocrin. 101, 1709-1715 Continuous administration of estetrol from a subcutaneous depot shows very weak uterotrophic activity and is considerably less potent than 17 ⁇ -estradiol and estriol.
- estetrol is a weak estrogen.
- the estrogenic potency of estetrol has been found to be much lower than that of a relatively weak estrogen that is commonly used in pharmaceutical formulations, namely 17 ⁇ -estradiolWith these findings in mind, it is not surprising that the interest in estetrol has dwindled since the early eighties and that no publications on the properties of estetrol have been issued since.
- One aspect of the invention concerns a cosmetic method of treating human skin by delivering an estrogenic component to said skin, the method comprising applying to the skin a composition containing: (i) at least 5 ⁇ g/g of an estrogenic component selected from the group consisting of: substances represented by the following formula
- R 1 ⁇ R 2 , R 3 , R 4 independently are a hydrogen atom, a hydroxyl group or an alkoxy group with 1-5 carbon atoms; each of R 5 , Re, R 7 is a hydroxyl group; no more than 3 of Ri, R 2 , R 3 , R 4 are hydrogen atoms; precursors capable of liberating a substance according to the aforementioned formula when used in the present method; and mixtures of one or more of the aforementioned substances and/or precursors; and (ii) a cosmetically acceptable vehicle.
- estrogenic component encompasses substances that are capable of triggering an estrogenic response in vivo, as well as precursors that are capable of liberating such an estrogenic component in vivo when used in accordance with the present invention, hi order for estrogenic components to trigger such a response they normally have to bind to an estrogen receptor, which receptors are found in various tissues within the mammalian body. It is noted that the present invention not only encompasses the use of estrogenic substances specifically mentioned in this application, but also metabolites of these hormones that display comparable in vivo functionality. In this context it is observed that, for instance, estriol is a metabolite of 17 ⁇ -estradiol.
- the terminology "delivering the estrogenic component to the skin” relates to the application of said estrogenic component to the surface of the skin, in particular topical application or transdermal application.
- Topical application suitably includes the application of e.g. salves, lotions and creams to the skin surface.
- Transdermal application encompasses the fixation to the skin epithelium of transdermal patches that contain the present composition.
- An important benefit of the present method resides in the ability of the present estrogenic components to enhance proliferation of fibroblasts and/or epidermal cells.
- the present composition is applied in an effective amount to enhance proliferation of fibroblasts and/or epidermal skin cells.
- Enhanced proliferation will induce a "rejuvenation" of the skin as demonstrated by increased elasticity and firmness of the skin, reduced wrinkle depth and pore sizes and/or increased skin moisture
- the benefits of the present method manifest themselves in the form of improved skin thickness and/or skin elasticity, provided the composition is applied in an effective amount.
- a particularly preferred embodiment of the present invention relates to a cosmetic method, wherein the present composition is applied in an effective amount to improve or prevent the condition of wrinkled, lined, dry, flaky, aged or photodamaged skin.
- the present invention is perfectly suitable for treating hypoestrogenic subjects, e.g.
- hypoestrogenism e.g. osteoporosis and climacteric symptoms (e.g. hot flushes, palpitations and mood disturbances).
- symptoms of hypoestrogenism are more effectively treated by e.g. oral or subcutaneous administration.
- the present estrogenic substances are distinct from both the estrogens that are commonly applied in pharmaceutical formulations (e.g. 17 ⁇ -ethinyl estadiol and 17/3- estradiol) in that they contain at least 4 hydroxyl groups.
- the present substances are particularly special in that the 5 membered ring in the steroid skeleton comprises 3 hydroxyl substituents rather than 0-2.
- Known estrogens that contain at least 4-hydroxyl groups and derivatives thereof are:
- the estrogemc substance applied as the active component in the present composition is a so called biogenic estrogen, i.e. an estrogen that occurs naturally in the human body, or a precursor thereof.
- biogenic estrogens are naturally present in the fetal and female body, side-effects are not expected to occur, particularly not if the serum levels resulting from the exogenous administration of such estrogens do not exceed naturally occurring concentrations. Since estetrol serum levels in the fetus are several times higher than those found in pregnant females and knowing that the fetus is particularly vulnerable, estetrol is deemed to be a particularly safe biogenic estrogen.
- the estrogenic substance contains 4 hydroxyl groups.
- Ri preferably represents a hydrogen atom. In said formula preferably at least 2, more preferably at least 3 of the groups Ri, R 2 , R 3 and R 4 represent a hydrogen atom.
- estrogemc substances according to the formula encompass various enantiomers since the carbon atoms that carry hydroxyl-substituents R 5 , Re and R 7 are chirally active.
- the present estrogenic substance is 15 ⁇ -hydroxy substituted.
- the substance is 16 ⁇ -hydroxy substituted.
- the substances is 17/3-hydroxy substituted.
- the estrogenic substances are 15 ⁇ ,16 ⁇ ,17 ⁇ -trihydroxy substituted.
- R 3 represents a hydroxyl group or an alkoxy group.
- the groups Ri, R 2 and * represent hydrogen atoms, in which case, if R 3 , R 5 , Re and R 7 are hydroxyl groups, the substance is 1,3,5 (10)-estratrien-3, 15,16,17-tetrol.
- a preferred isomer of the latter substance is 1,3,5 (10)-estratrien-3, 15 ⁇ ,16 ⁇ ,17 ⁇ -tetrol (estetrol).
- the invention also encompasses the use of precursors of the estrogenic substances that constitute the active component in the present method. These precursors are capable of liberating the aforementioned estrogenic substances when used in the present method, e.g. as a result of metabolic conversion.
- precursors are preferably selected from the group of andro genie precursors as well as derivatives of the present estrogenic substances.
- Suitable examples of androgenic precursors include androgens that can be converted into the present estrogenic substances through in vivo aromatisation.
- Examples of derivatives of the present estrogenic substances that can suitably be used as precursors include such substances wherein the hydrogen atom of at least one of the hydroxyl groups has been substituted by an acyl radical of a hydrocarbon carboxylic, sulfonic acid or sulfamic acid of 1-25 carbon atoms; tetrahydrofuranyl; tetrahydropyranal; or a straight or branched chain glycosydic residue containing 1-20 glycosidic units per residue.
- Typical examples of precursors which can suitably be used in accordance with the invention are esters that can be obtained by reacting the hydroxyl groups of the estrogenic substances with substances that contain one or more carboxy (M* OOC-) groups, wherein M 1" represents a hydrogen or (akali)metal cation.
- the precursors are derivatives of the estrogenic substances, wherein the hydrogen atom of at least one of the hydroxyl groups in said formula has been substituted by -CO-R, wherein R is a hydrocarbon radical comprising from 1-25 carbon atoms.
- R is hydrogen, or an alkyl, alkenyl or aryl radical comprising from 1-20 carbon atoms.
- composition that is applied to the skin in accordance with the present invention suitably contains at least 10 ⁇ g/g of the estrogenic component. Particularly satisfactory results can be obtained if the composition contains at least 30 ⁇ g/g, more preferably at least 50 ⁇ g/g and most preferably at least 100 g/g of the estrogenic component. For practical reasons the present composition will usually not contain more than 50 mg/g of the estrogenic component. Preferably said composition contains not more than 20 mg/g, more preferably not more than 10 mg/g of the estrogenic component.
- the advantages of the present invention maybe realised in skin as it is found in different places of the human body. Particularly advantageous results can be obtained by applying the composition to e.g. face, neck, shoulders, breast, buttocks (cellulitis) etc.
- the skin care composition is applied to facial skin or the skin of the neck. hi order to obtain quick and lasting results it is advisable to apply the present composition at least once a day during a period of at least 3 days, particularly in case of topical application. Because transdermal application enables the relatively slow release of the present estrogenic component over a longer period of time, transdermal application is preferably carried out with a frequency of at least once a week.
- Topical application of the estrogenic component is the preferred mode of administration as it is uncomplicated, effective and produces essentially no undesirable side-effects.
- the topical application of the present composition is preferably carried out in such a way that virtually all of the composition that has been applied to the skin, is allowed to penetrate said skin.
- a small quantity of the present composition for example from 0.1 to 100 g, is applied directly to the skin, optionally from a suitable container or applicator and, if necessary, it is then spread over and/or rubbed into the skin using the hand or fingers or a suitable device.
- the present method preferably, comprises administering the estrogenic component for a period of at least 1 week, more preferably of at least 3 weeks.
- the present method usually employs uninterrupted administration of the estrogenic component during at least 10, preferably at least 20 days.
- the term "uninterrupted" as used in here means that the estrogenic component is administered at relatively regular intervals, with no (therapeutically) significant interruptions. Naturally, minor interruptions may occur that do not affect the overall effectiveness of the present method, and indeed such aberrations are encompassed by the present invention.
- the administration regimen is deemed to be uninterrupted if the longest interval between 2 subsequent administrations is not more than 3.5 times as long as the average interval. Even more preferably said longest interval is not more than 2.5 times, most preferably not more than 1.5 times as long as the average interval.
- Another aspect of the invention relates to a method of treating or preventing vaginal dryness, wherein the method comprises applying to the vaginal epithelium a composition containing:
- a further aspect of the invention relates to a method of promoting wound healing, wherein the method comprises applying to the wounded tissue or to tissue in the vicinity of the wound a composition containing: (i) at least 5 ⁇ g/g of said estrogenic component; and (ii) a cosmetically acceptable vehicle.
- Yet another aspect of the invention relates a method of treating or preventing acne, wherein the method comprises applying to the skin that is affected by acne or that is at risk of being affected by acne a composition containing: (i) at least 5 ⁇ g/g of said estrogenic component; and (ii) a cosmetically acceptable vehicle.
- Yet another aspect of the invention relates to a skin care composition for topical administration, in accordance with the method described herein before, said composition containing: (i) at least 5 ⁇ g/g of the estrogenic component; and (ii) a cosmetically acceptable vehicle.
- the composition according to the invention comprises a cosmetically acceptable vehicle to act as a diluant, dispersant or carrier for the estrogenic component, so as to facilitate its distribution when the composition is applied to the skin.
- Vehicles other than or in addition to water can include liquid or solid emollients, solvents, humectants, thickeners and powders.
- Particularly suitable nonaqueous carriers include polydimethyl siloxane and/or polydimethyl phenyl siloxane.
- Particular desirable are mixtures of low and high viscosity silicones. These silicones are available from the General Electric Company under trademarks Vicasil, SE and SF and from the Dow Corning Company under the 200 and 550 Series.
- the amounts of silicone which can be utilised in the compositions of this invention can range anywhere from 5% to 95%, preferably from 25% to 90% by weight of the composition.
- the cosmetically acceptable vehicle will usually form from 5% to 99.9%, preferably from 25% to 95% by weight of the composition, and can, in the absence of other cosmetic adjuncts, form the balance of the composition.
- the vehicle is at least 80 wt. % water.
- water constitutes at least 50 wt. % of the present composition, most preferably from 60 to 80 wt. %, by weight of the composition.
- the skin care composition of the present invention may contain an oil or lipid material, together with an emulsifier, to provide either a water-in-oil emulsion or an oil-in- water emulsion, depending largely on the average hydrophilic-lipophilic balance (HLB) of the emulsifier employed.
- the present compositions include sunscreens. Sunscreens include those materials commonly employed to block ultraviolet light. Illustrative compounds are the derivatives of P ABA, cinnamate and salicylate. For example, octyl methoxycinnamate and 2- hydroxy-4-methoxy benzophenone (also known as oxybenzone) can be used.
- Octyl methoxycinnamate and 2-hydroxy-4-methoxy benzophenone are commercially available under the trademarks, Parsol MCX and Benzophenone-3, respectively.
- the exact amount of sunscreen employed in the emulsions can vary depending upon the degree of protection desired from the sun's UV radiation.
- Emollients can advantageously be incorporated into the compositions of the present invention. Levels of such emollients may range from 0.5% to 50%, preferably from 5% and 30% by weight of the total composition. Emollients may be classified under such general chemical categories as esters, fatty acids and alcohols, polyols and hydrocarbons. Esters may be mono- or di-esters. Acceptable examples of fatty di-esters include dibutyl adipate, diethyl sebacate, diisopropyl dimerate, and dioctyl succinate. Acceptable branched chain fatty esters include 2-ethyl-hexyl myristate, isopropyl stearate and isostearyl pahnitate.
- Acceptable tribasic acid esters include triisopropyl trilinoleate and trilauryl citrate.
- Acceptable straight chain fatty esters include lauryl pahnitate, myristyl lactate, and stearyl oleate.
- Preferred esters include coco-caprylate/caprate (a blend of coco-caprylate and coco-caprate), propylene glycol myristyl ether acetate, diisopropyl adipate and cetyl octanoate.
- Suitable fatty alcohols and acids include those compounds having from 10 to 20 carbon atoms. Especially preferred are such compounds such as cetyl, myristyl, palmitic and stearyl alcohols and acids.
- polyols which may serve as emollients are linear and branched chain alkyl polyhydroxyl compounds.
- propylene glycol, sorbitol and glycerin are preferred.
- polymeric polyols such as poly-propylene glycol and polyethylene glycol.
- Butylene and propylene glycol are also especially preferred as penetration enhancers.
- Exemplary hydrocarbons which may serve as emollients are those having hydrocarbon chains anywhere from 12 to 30 carton atoms. Specific examples include mineral oil, petroleum jelly, squalene and isoparaffins.
- Another category of functional ingredients that may be employed in the cosmetic compositions of the present invention are thickeners.
- a thickener will usually be present in amounts anywhere from 0.1 to 20% by weight, preferably from about 0.5% to 10% by weight of the composition.
- Exemplary thickeners are cross-linked polyacrylate materials available under the trademark Carbopol from the B.F. Goodrich Company. Gums may be employed such as xanthan, carrageenan, gelatin, karaya, pectin and locust beans gum. Under certain circumstances the thickening function may be accomplished by a material also serving as a silicone or emollient. For instance, silicone gums in excess of 10 centistokes and esters such as glycerol stearate have dual functionality.
- Powders may also be incorporated into the composition of the invention. These powders include chalk, talc, kaolin, starch, smectite clays, chemically modified magnesium aluminium silicate, organically modified montmorillonite clay, hydrated aluminium silicate, fumed silica, aluminium starch octenyl succinate and mixtures thereof.
- adjunct minor components may also be incorporated into the present compositions. These ingredients may include colouring agents, opacifiers and perfumes. Amounts of these other adjunct minor components may range anywhere from 0:001% up to 20% by weight of the composition.
- the topical skin care composition of the invention can be formulated e.g. as a lotion, a cream or a salve (e.g. a gel).
- the composition can be packaged in a suitable container to suit its viscosity and intended use by the consumer.
- a lotion or a cream can be packaged in a bottle or a roll-ball applicator, or a propellant-driven aerosol device or a container fitted with a pump suitable for finger operation.
- the composition When the composition is a cream or a salve, it can simply be stored in a non-deformable bottle or squeeze container, such as a tube or a lidded jar.
- the composition may also be included in capsules such as those described in U.S. Pat. No. 5,063,507, incorporated by reference herein.
- the invention accordingly also provides a closed container containing a cosmetically acceptable composition as herein defined.
- Recombinant human ER ⁇ or ER ⁇ proteins were dissolved in binding buffer (10 mM Tris-HCL, pH 7.5, 10% glycerol, 1 mM DTT, 1 mg/ml BSA) and duplicate aliquots were then incubated with [ 3 H]E2 at a final concentration of 0.5 nM, together with a vehicle control (0.4% DMSO), or the same amount of vehicle containing increasing concentrations of unlabeled steroid ligands as competitors. After incubation for 2 h at 25°C, the unbound ligands were removed and the amounts of [ 3 H]E2 bound to either ER ⁇ or ER ⁇ proteins were measured.
- binding buffer 10 mM Tris-HCL, pH 7.5, 10% glycerol, 1 mM DTT, 1 mg/ml BSA
- Table 1 Percent inhibition of specific binding to ER ⁇ and ER ⁇ proteins using E4 as unlabeled steroid ligand and 0.5 nM [3H] as labeled competitor. Results of three separate experiments are shown.
- Sprague Dawley rats was determined after a single subcutaneous administration (sc) at several dose levels.
- Female Sprague Dawley rats were equipped with a permanent silatic heart catheter, as described by Kuipers et al. (1985, Gastroenterology, 88, 403-411). Rats were allowed to recover from surgery for 5 days and were than administered 0.05, 0.5, or 5 mg/kg E4 in 0.5 ml arachidis oil. E4 was injected in the neck area using a 1 ml syringe and 20g needle. Blood samples were subsequently collected via the heart catheter in heparinized tubes at 0.5, 1, 2, 4, 8 and 24 hours.
- Erythrocytes were removed by centrifugation at 5000xg for 10 minutes at 4°C and blood plasma was stored at -20°C. After thawing the plasma samples, liquid-liquid extraction (hexane and diethyl ether) was employed to prepare the E4-containing plasma samples for HPLC analysis (Perkin Elmer 200) and tandem mass spectrometry using a PE Sciex 3000 tandem mass spectrometer and APCI interface. With each sample batch, a calibration curve with 6 calibrators was recorded. The calibration curve was calculated using linear regression (correlation coefficient > 0.98), which permitted quantitation of plasma concentrations. For each rat plasma, sampled at different time intervals, data were collected.
- Plasma E4 concentration data were analysed with "WinNonLin, edition 3.1" and involved pharmacokinetic parameters for C max , AUCo- 24 and half-life. Interestingly, E4 demonstrated good stability with a relatively long half-life of 2-3 hours, enabling the detection of bioactive levels of unconjugated E4 at all time points over a 24 hour interval.
- the first component of the study is qualitative by making an evaluation of improvement in the patient's appearance. This evaluation requires a baseline level for future comparison.
- An initial baseline value is created in the form of a standardised set of questions as to how the patient views her own appearance, photographs of the patient, and a psychological profile of the patient's self-image.
- the second component is quantitative, including the measurement of urinary excretion of hydroxyproline, moisture content of the skin, glycosaminoglycans in the skin, and changes in resilience and pliability of the skin. Methods for determining these factors are found in "The Menopause”, Ed. R. I. Beard, University Press, Chapter 7 (1977) and “Methods in Skin Research", Ed. Skerrow, D. and Skerrow C. J., John Wiley & Sons Ltd., Chp. 22, “Analysis of Sebaceous Lipids", p. 587-608 (1985), and further references cited therein, all herein incorporated by reference. Again, before the start of the study baseline values of these quantitative factors are obtained.
- the study volunteers are subsequently placed in a clinical protocol receiving the topical compound formulation as set forth in example 3.
- the compound formulation is administered to areas of the skin most effected by atrophy twice a day, which is continued for 1 to 3 months. Evaluations, both quantitative and qualitative, are made at biweekly intervals.
- the compound formulation, as set forth in example 3 gives positive results in a majority of participating study subjects by improving the overall qualitative index of the patient's appearance and/or the quantitative parameters, e.g., an increase in the urinary excretion of hydroxyproline signifying an increase in turnover and synthesis of collagen, an increase in moisture content, glycosaminoglycans, pliability, or resilience of the skin.
- vaginal atrophy and/or vaginal dryness symptom associated with menopause are selected. These women are in general good health. Since the nature of this disorder is highly subjective, evaluation of the effectiveness of treatment is necessarily also subjective in nature. The female subjects are asked to keep a daily log, noting details as to the degree of vaginal itching, dryness and dyspareunia, and to use a visual analogue scale to record their subjective estimates. The change from pretreatment (base line value) during 1 to 3 months of treatment is assessed and considered to be indicative of the treatment efficacy.
- the study volunteers subsequently participate in a clinical protocol receiving the topical compound formulation as set forth in example 3.
- the compound formulation is administered intravaginally once a day, which is continued for 1 to 3 months. Evaluations of vaginal itching, dryness and dyspareunia are made at biweekly intervals. Utility of estetrol is demonstrated by the positive results observed in a majority of participating study subjects showing improvements in qualitative change from baseline value for vaginal itching, dryness and dyspareunia.
- estetrol 100 mg estetrol is thoroughly mixed with 99,9 gram of the above described ointment under aseptic conditions.
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/517,509 US7943604B2 (en) | 2002-06-11 | 2003-06-11 | Method of treating human skin and a skin care composition for use in such a method |
AU2003274941A AU2003274941A1 (en) | 2002-06-11 | 2003-06-11 | A method of treating human skin and a skin care composition for use in such a method |
EP03741632A EP1511498B1 (en) | 2002-06-11 | 2003-06-11 | A method of treating human skin and a skin care composition for use in such a method |
ES03741632T ES2399423T3 (en) | 2002-06-11 | 2003-06-11 | Method for treating human skin and a skin care composition for use in such method |
CA2489270A CA2489270C (en) | 2002-06-11 | 2003-06-11 | A method of treating human skin and a skin care composition for use in such a method |
US13/017,858 US9040509B2 (en) | 2002-06-11 | 2011-01-31 | Method of treating human skin and a skin care composition for use in such a method |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02077273.7 | 2002-06-11 | ||
EP02077273 | 2002-06-11 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US51750903A A-371-Of-International | 2002-06-11 | 2003-06-11 | |
US13/017,858 Division US9040509B2 (en) | 2002-06-11 | 2011-01-31 | Method of treating human skin and a skin care composition for use in such a method |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003103685A1 true WO2003103685A1 (en) | 2003-12-18 |
Family
ID=29724475
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/NL2003/000420 WO2003103685A1 (en) | 2002-06-11 | 2003-06-11 | A method of treating human skin and a skin care composition for use in such a method |
Country Status (7)
Country | Link |
---|---|
US (2) | US7943604B2 (en) |
EP (1) | EP1511498B1 (en) |
CN (1) | CN100352445C (en) |
AU (1) | AU2003274941A1 (en) |
CA (1) | CA2489270C (en) |
ES (1) | ES2399423T3 (en) |
WO (1) | WO2003103685A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008085038A2 (en) * | 2007-01-08 | 2008-07-17 | Pantarhei Bioscience B.V. | Method of treating or preventing infertility in a female mammal and pharmaceutical kit for use in such method |
EP2189788A1 (en) * | 2007-09-12 | 2010-05-26 | Kao Corporation | Method for quantification of steroid hormone |
WO2021044302A1 (en) | 2019-09-03 | 2021-03-11 | Richter Gedeon Nyrt. | Industrial process for the preparation of high purity estetrol |
WO2023094690A1 (en) | 2021-11-29 | 2023-06-01 | Estetra Srl | Compositions for promoting hair growth |
WO2023094689A1 (en) | 2021-11-29 | 2023-06-01 | Estetra Srl | Compositions for preventing or treating skin aging |
WO2024074700A1 (en) * | 2022-10-07 | 2024-04-11 | Neuralis Sa | Topical compositions comprising an estetrol component and use of said compositions for wound healing |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8924922B2 (en) * | 2010-06-14 | 2014-12-30 | Microsoft Corporation | Pre-compiling hosted managed code |
RS55293B1 (en) | 2011-06-01 | 2017-03-31 | Estetra Sprl | Process for the production of estetrol intermediates |
EP2714710B1 (en) | 2011-06-01 | 2016-04-06 | Estetra S.P.R.L. | Process for the production of estetrol intermediates |
EP2383279A1 (en) | 2011-07-19 | 2011-11-02 | Pantarhei Bioscience B.V. | Process for the preparation of estetrol |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
PT2782584T (en) | 2011-11-23 | 2021-09-02 | Therapeuticsmd Inc | Natural combination hormone replacement formulations and therapies |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
WO2013034780A2 (en) | 2012-12-20 | 2013-03-14 | Crystal Pharma, S.A.U. | Process for the preparation of estetrol and related compounds |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
CA2924255C (en) | 2013-09-18 | 2022-11-22 | Crystal Pharma, S.A.U. | Process for the preparation of estetrol |
AR100562A1 (en) | 2014-05-22 | 2016-10-12 | Therapeuticsmd Inc | PHARMACEUTICAL COMPOSITION OF ESTRADIOL AND PROGESTERONE FOR HORMONAL REPLACEMENT THERAPY |
MD3310346T2 (en) | 2015-06-18 | 2021-06-30 | Estetra Sprl | Orodispersible tablet containing estetrol |
DK3310345T3 (en) | 2015-06-18 | 2021-05-25 | Estetra Sprl | ORODISPERSIBLE TABLET CONTAINING ESTETROL |
DK3106148T3 (en) | 2015-06-18 | 2018-05-07 | Mithra Pharmaceuticals S A | Orodispersible dosing unit containing an estetrol component |
EA035687B1 (en) | 2015-06-18 | 2020-07-27 | Эстетра Спрл | Orodispersible dosage unit containing an estetrol component |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
CA3020153A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
WO2017173044A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd Inc. | Steroid hormone compositions in medium chain oils |
KR20220144885A (en) | 2016-08-05 | 2022-10-27 | 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 | Method for the management of dysmenorrhea and menstrual pain |
TWI801561B (en) | 2018-04-19 | 2023-05-11 | 比利時商依思特拉私人有限責任公司 | Compounds and their uses for alleviating menopause-associated symptoms |
JOP20200260A1 (en) | 2018-04-19 | 2019-10-19 | Estetra Sprl | Compounds and their uses for alleviating menopause-associated symptoms |
US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000062753A1 (en) * | 1999-04-16 | 2000-10-26 | Jenapharm Gmbh & Co. Kg | Pharmaceutical or cosmetic compositions for the local, intradermal application of hormones |
WO2003018026A1 (en) * | 2001-08-31 | 2003-03-06 | Pantarhei Bioscience B.V. | Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3440320A (en) * | 1964-06-18 | 1969-04-22 | Mortimer D Sackler | Chelated suppository and method of using same |
US3797494A (en) * | 1969-04-01 | 1974-03-19 | Alza Corp | Bandage for the administration of drug by controlled metering through microporous materials |
DE2426779A1 (en) | 1974-05-31 | 1975-12-18 | Schering Ag | 1,3-disubstd. 8 alpha oestratrienes - oestrogens with minimal uterotropic activity |
DE2336434A1 (en) | 1973-07-13 | 1975-04-17 | Schering Ag | 1,3-disubstd. 8 alpha oestratrienes - oestrogens with minimal uterotropic activity |
DE2336433A1 (en) | 1973-07-13 | 1975-04-03 | Schering Ag | 1,3-disubstd. 8 alpha oestratrienes - oestrogens with minimal uterotropic activity |
US4722941A (en) * | 1978-06-07 | 1988-02-02 | Kali-Chemie Pharma Gmbh | Readily absorbable pharmaceutical compositions of per se poorly absorbable pharmacologically active agents and preparation thereof |
US4460372A (en) * | 1981-02-17 | 1984-07-17 | Alza Corporation | Percutaneous absorption enhancer dispenser for use in coadministering drug and percutaneous absorption enhancer |
US4573996A (en) * | 1984-01-03 | 1986-03-04 | Jonergin, Inc. | Device for the administration of an active agent to the skin or mucosa |
US4624665A (en) * | 1984-10-01 | 1986-11-25 | Biotek, Inc. | Method of transdermal drug delivery |
US4937238A (en) * | 1986-03-04 | 1990-06-26 | The Board Of Regents Of The University Of Nebraska | Prevention of mammary carcinoma |
US4762717A (en) * | 1986-03-21 | 1988-08-09 | The General Hospital Corporation | Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for use as a contraceptive |
US5223261A (en) * | 1988-02-26 | 1993-06-29 | Riker Laboratories, Inc. | Transdermal estradiol delivery system |
US5043331A (en) | 1989-06-15 | 1991-08-27 | Orion-Yhtyma Oy | Treatment of postmenopausal disorders |
US5130137A (en) * | 1989-08-09 | 1992-07-14 | The General Hospital Corporation | Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for use in treating benign ovarian secretory disorders |
JPH04235171A (en) | 1990-07-26 | 1992-08-24 | Sumitomo Chem Co Ltd | Sulfohydroxamic acid derivative, production thereof and herbicide containing the same derivative as active ingredient |
US5063507A (en) * | 1990-09-14 | 1991-11-05 | Plains Cotton Cooperative Association | Goods database employing electronic title or documentary-type title |
US5211952A (en) * | 1991-04-12 | 1993-05-18 | University Of Southern California | Contraceptive methods and formulations for use therein |
US5340586A (en) * | 1991-04-12 | 1994-08-23 | University Of Southern California | Methods and formulations for use in treating oophorectomized women |
US5340585A (en) * | 1991-04-12 | 1994-08-23 | University Of Southern California | Method and formulations for use in treating benign gynecological disorders |
US5468736A (en) * | 1993-02-25 | 1995-11-21 | The Medical College Of Hampton Road | Hormone replacement therapy |
US5895783A (en) | 1993-07-16 | 1999-04-20 | Schering Aktiengesellschaft | Treatment of preeclampsia and preterm labor with combination of progestational agent and a nitric oxide synthase substrate and/or donor |
NL9301562A (en) * | 1993-09-09 | 1995-04-03 | Saturnus Ag | Substitution therapy preparation. |
DE4344405C2 (en) * | 1993-12-24 | 1995-12-07 | Marika Dr Med Ehrlich | Anti-ovulation agent and method for hormonal contraception |
AU2103495A (en) | 1994-08-04 | 1996-03-04 | Biex, Inc. | Method for prediction of premature delivery using estetrol (e4) as an indicator |
DE4429374C1 (en) * | 1994-08-12 | 1996-02-01 | Jenapharm Gmbh | Pharmaceutical preparations for contraception / hormone substitution with biogenic estrogen component |
EP0994718B1 (en) | 1997-06-20 | 2005-08-17 | Akzo Nobel N.V. | Gonadotropin releasing hormone antagonist |
DE19739916C2 (en) * | 1997-09-11 | 2001-09-13 | Hesch Rolf Dieter | Use of a combination of a progestogen and an estrogen for the continuous inhibition of ovulation and possibly simultaneous treatment and / or prophylaxis of tumors of the mammary glands |
US6214815B1 (en) * | 1998-12-23 | 2001-04-10 | Ortho-Mcneil Pharmaceuticals, Inc. | Triphasic oral contraceptive |
DE19917930A1 (en) | 1999-04-15 | 2000-10-19 | Schering Ag | Treating estrogen deficiency associated disorders, e.g. menopausal problems, osteoporosis, neoplasia or neurodegenerative disease, using new or known ent-steroids having bone-selective estrogenic activity |
US7273932B1 (en) | 1999-05-28 | 2007-09-25 | The University Of Cincinnati | Antisense oligonucleotides for fertility and menstrual cycle regulation and for chemopreventive and chemotherapeutic use |
WO2001030356A1 (en) | 1999-10-25 | 2001-05-03 | Laboratoire Theramex | Hormonal composition based on a progestational agent and an oestrogen and use thereof |
CA2408935A1 (en) | 2000-05-12 | 2001-11-15 | Halina Offner | Method of treating immune pathologies with low dose estrogen |
US20040192598A1 (en) * | 2000-10-11 | 2004-09-30 | Laura Kragie | Composition and method of alleviating adverse side effects and/or enhancing efficacy of agents that inhibit aromatase |
US6936599B2 (en) * | 2001-04-25 | 2005-08-30 | The Regents Of The University Of California | Estriol therapy for multiple sclerosis and other autoimmune diseases |
EP1260225A1 (en) | 2001-05-18 | 2002-11-27 | Pantarhei Bioscience B.V. | A pharmaceutical composition for use in hormone replacement therapy |
-
2003
- 2003-06-11 US US10/517,509 patent/US7943604B2/en active Active
- 2003-06-11 EP EP03741632A patent/EP1511498B1/en not_active Expired - Lifetime
- 2003-06-11 WO PCT/NL2003/000420 patent/WO2003103685A1/en not_active Application Discontinuation
- 2003-06-11 AU AU2003274941A patent/AU2003274941A1/en not_active Abandoned
- 2003-06-11 CA CA2489270A patent/CA2489270C/en not_active Expired - Lifetime
- 2003-06-11 ES ES03741632T patent/ES2399423T3/en not_active Expired - Lifetime
- 2003-06-11 CN CNB038188449A patent/CN100352445C/en not_active Expired - Lifetime
-
2011
- 2011-01-31 US US13/017,858 patent/US9040509B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000062753A1 (en) * | 1999-04-16 | 2000-10-26 | Jenapharm Gmbh & Co. Kg | Pharmaceutical or cosmetic compositions for the local, intradermal application of hormones |
WO2003018026A1 (en) * | 2001-08-31 | 2003-03-06 | Pantarhei Bioscience B.V. | Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy |
Non-Patent Citations (4)
Title |
---|
A. O. MUECK, H. SEEGER, C. LIPPERT & D. WALLWIENER: "Angiogenetic and anti-angiogenetic effects of estradiol and its metabolites.", J. CLIN. BASIC CARDIOL., vol. 4, no. 2, 2001, pages 153 - 155, XP008004903 * |
J.B. SCHMIDT, M. BINDER, G. DEMSCHIK, C. BIEGLMAYER & A. REINER: "Treatment of skin aging with topical estrogens", INT. J. DERMATOL., vol. 35, no. 9, 1996, pages 669 - 674, XP002220744 * |
M. G. SHAH & H. I. MAIBACH: "Estrogen and skin. An overview", AM. J. CLIN. DERMATOL., vol. 2, no. 3, 2001, pages 143 - 150, XP002220743 * |
R. SITRUK-WARE & J.-L. THOMAS: "Local hormonal treatment for urogenital atrophy after menopause", SCHWEIZ. RUNDSCH. MED. PRAXIS, vol. 86, no. 33, 1997, pages 1245 - 1248, XP001119587 * |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008085038A2 (en) * | 2007-01-08 | 2008-07-17 | Pantarhei Bioscience B.V. | Method of treating or preventing infertility in a female mammal and pharmaceutical kit for use in such method |
WO2008085038A3 (en) * | 2007-01-08 | 2008-09-12 | Pantarhei Bioscience Bv | Method of treating or preventing infertility in a female mammal and pharmaceutical kit for use in such method |
CN101583363B (en) * | 2007-01-08 | 2013-08-21 | 潘塔希生物科学股份有限公司 | Method of treating or preventing infertility in a female mammal and pharmaceutical kit for use in such method |
EP2189788A1 (en) * | 2007-09-12 | 2010-05-26 | Kao Corporation | Method for quantification of steroid hormone |
EP2189788A4 (en) * | 2007-09-12 | 2010-10-13 | Kao Corp | Method for quantification of steroid hormone |
US8017404B2 (en) | 2007-09-12 | 2011-09-13 | Kao Corporation | Steroid hormone assay method |
WO2021044302A1 (en) | 2019-09-03 | 2021-03-11 | Richter Gedeon Nyrt. | Industrial process for the preparation of high purity estetrol |
US11633406B2 (en) | 2019-09-03 | 2023-04-25 | Richter Gedeon Nyrt. | Industrial process for the preparation of high purity estetrol |
WO2023094690A1 (en) | 2021-11-29 | 2023-06-01 | Estetra Srl | Compositions for promoting hair growth |
WO2023094689A1 (en) | 2021-11-29 | 2023-06-01 | Estetra Srl | Compositions for preventing or treating skin aging |
WO2024074700A1 (en) * | 2022-10-07 | 2024-04-11 | Neuralis Sa | Topical compositions comprising an estetrol component and use of said compositions for wound healing |
Also Published As
Publication number | Publication date |
---|---|
US9040509B2 (en) | 2015-05-26 |
EP1511498A1 (en) | 2005-03-09 |
CN100352445C (en) | 2007-12-05 |
US7943604B2 (en) | 2011-05-17 |
CA2489270A1 (en) | 2003-12-18 |
AU2003274941A1 (en) | 2003-12-22 |
CN1674915A (en) | 2005-09-28 |
ES2399423T3 (en) | 2013-04-01 |
CA2489270C (en) | 2012-08-07 |
US20050215538A1 (en) | 2005-09-29 |
EP1511498B1 (en) | 2012-11-21 |
US20110160173A1 (en) | 2011-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9040509B2 (en) | Method of treating human skin and a skin care composition for use in such a method | |
Creidi et al. | Effect of a conjugated oestrogen (Premarin®) cream on ageing facial skin. A comparative study with a placebo cream | |
DE60216630T2 (en) | USE OF ESTROGEN IN COMBINATION WITH PROGESTOGEN FOR HORMONE SUBSTITUTIONAL THERAPY | |
US8076314B2 (en) | Topical compositions for anti-aging and methods of using same | |
DE60209907T2 (en) | USE OF ORGANIC COMPOUNDS TO INCREASE LIBIDO IN WOMEN | |
Diamond et al. | Metabolic effects of 12-month percutaneous dehydroepiandrosterone replacement therapy in postmenopausal women | |
JP4841778B2 (en) | Cosmetic composition containing resveratrol and retinoid | |
EP0189738A1 (en) | Topical compositions for preventing or treating dry skin | |
EP1003470B1 (en) | Skin care composition | |
NICHOLS et al. | 17β-Estradiol for postmenopausal estrogen replacement therapy | |
DE60223795T2 (en) | Tetrahydroxylated estrogen-containing drug delivery system for use in hormonal contraception | |
WO2006125642A1 (en) | Methods and apparatus for transdermal or transmucosal application of testosterone | |
CA2585666A1 (en) | Use of androgens to reduce the likelihood of acquiring or to treat skin aging | |
Hall et al. | Skin and hormone therapy | |
Murray | Natural progesterone: what role in women’s health care | |
Marks et al. | Skin changes at the time of the climacteric | |
EP0630248B1 (en) | Use of estriol for the manufacture of a transdermal therapeutic system for treating climacteric osteoporosis | |
NZ210943A (en) | Dehydroepiandrosterone compositons for skin treatment | |
AU2004222794A1 (en) | Non-oral androgenic steroids for women |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2489270 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003741632 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20038188449 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2003741632 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10517509 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |